Details

Autor(en) / Beteiligte

• Johnson, Douglas B
• Balko, Justin M
• Compton, Margaret L
• Chalkias, Spyridon
• Gorham, Joshua
• Xu, Yaomin
• Hicks, Mellissa
• Puzanov, Igor
• Alexander, Matthew R
• Bloomer, Tyler L
• Becker, Jason R
• Slosky, David A
• Phillips, Elizabeth J
• Pilkinton, Mark A
• Craig-Owens, Laura
• Kola, Nina
• Plautz, Gregory
• Reshef, Daniel S
• Deutsch, Jonathan S
• Deering, Raquel P
• Olenchock, Benjamin A
• Lichtman, Andrew H
• Roden, Dan M
• Seidman, Christine E
• Koralnik, Igor J
• Seidman, Jonathan G
• Hoffman, Robert D
• Taube, Janis M
• Diaz, Luis A
• Anders, Robert A
• Sosman, Jeffrey A
• Moslehi, Javid J

Titel

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Ist Teil von

• The New England journal of medicine, 2016-11, Vol.375 (18), p.1749-1755

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Fatal autoimmune myocarditis with rhabdomyolysis and refractory arrhythmias developed in two patients treated with a combination of anti–CTLA-4 and anti–PD-1 blockers. On histologic examination, a myocardial infiltrate suggested acute cardiac allograft rejection. Immune checkpoint inhibitors have transformed the treatment of several cancers by releasing restrained antitumor immune responses. 1 Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody, and nivolumab, an anti–programmed death-1 (PD-1) antibody, have individually improved survival in patients with melanoma, and early results suggest that their combination further enhances antitumor activity and survival. 2 – 5 Other adverse events associated with these agents include dermatitis, endocrinopathies, colitis, hepatitis, and pneumonitis, which are all thought to arise from aberrant activation of autoreactive T cells. 6 , 7 These toxic effects are more frequent and severe when ipilimumab and nivolumab are used in combination. 4 Here, we report . . .